Ruxolitinib (Jakafi) - Oncology Nurse Advisor

Ruxolitinib (Jakafi)

Slideshow

  • Slide

  • Slide

  • Slide

  • You can skip this ad in 3 seconds.
  • Slide

  • Slide

  • Slide

  • You can skip this ad in 3 seconds.
  • Slide

  • Slide

  • Slide

  • You can skip this ad in 3 seconds.
  • Slide

  • Slide

  • Slide

  • You can skip this ad in 3 seconds.
  • Slide

  • Slide

  • Slide

  • You can skip this ad in 3 seconds.
  • Slide

  • Slide

  • Slide

  • You can skip this ad in 3 seconds.
  • Slide

  • Slide

  • Slide

  • You can skip this ad in 3 seconds.
  • Slide

  • Slide

  • Slide

  • You can skip this ad in 3 seconds.
  • Slide

  • Slide

  • Slide

  • You can skip this ad in 3 seconds.
  • Slide

  • Slide

This slideshow reviews ruxolitinib (Jakafi), indicated for intermediate or high-risk myelofibrosis, and polycythemia vera in cases of inadequate response or intolerance of hydroxyurea.

Table of Contents

Slide 4: Dosage and Administration
Slide 17: Cautions, Effects, and Interactions
Slide 24: What to Tell Your Patient
Slide 29: Reference